Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 93253, 10 pages
http://dx.doi.org/10.1155/MI/2006/93253
Research Communication

Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver Cirrhosis

Department of Gastroenterology, Renmin Hospital, Wuhan University, Wuhan 430060, China

Received 15 December 2005; Accepted 13 March 2006

Copyright © 2006 Peng Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B Madan, A K Prasad, V S Parmar, and B Ghosh, “1,4-Dihydroxyxanthone modulates the adhesive property of endothelial cells by inhibiting intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin,” Bioorganic and Medicinal Chemistry, vol. 12, no. 6, pp. 1431–1437, 2004. View at Publisher · View at Google Scholar
  2. R Volpes, J J Van den Oord, and V J Desmet, “Immunohistochemical study of adhesion molecules in liver inflammation,” Hepatology, vol. 12, no. 1, pp. 59–65, 1990. View at Google Scholar
  3. C M Bruno, C Sciacca, D Cilio et al., “Circulating adhesion molecules in patients with virus-related chronic diseases of the liver,” World Journal of Gastroenterology, vol. 11, no. 29, pp. 4566–4569, 2005. View at Google Scholar
  4. J A Girón-González, C Martínez-Sierra, C Rodriguez-Ramos et al., “Adhesion molecules as a prognostic marker of liver cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 40, no. 2, pp. 217–224, 2005. View at Google Scholar
  5. H Yokomori, M Oda, M Ogi et al., “Expression of adhesion molecules on mature cholangiocytes in canal of Hering and bile ductules in wedge biopsy samples of primary biliary cirrhosis,” World Journal of Gastroenterology, vol. 11, no. 28, pp. 4382–4389, 2005. View at Google Scholar
  6. A Panasiuk, D Prokopowicz, and B Panasiuk, “Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C,” World Journal of Gastroenterology, vol. 10, no. 24, pp. 3639–3642, 2004. View at Google Scholar
  7. J W Ho, R T Poon, C S Tong, and S T Fan, “Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 10, no. 14, pp. 2014–2018, 2004. View at Google Scholar
  8. H Yokomori, M Oda, K Yoshimura et al., “Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 protein and messenger RNA in primary biliary cirrhosis,” Internal Medicine, vol. 42, no. 10, pp. 947–954, 2003. View at Google Scholar
  9. C Pata, A Yazar, E Altintas et al., “Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis,” Hepato-Gastroenterology, vol. 50, no. 51, pp. 794–797, 2003. View at Google Scholar
  10. A Abdalla, A-A G Sheesha, M Shokeir et al., “Serum intercellular adhesion molecule-I in children with chronic liver disease: relationship to disease activity,” Digestive Diseases and Sciences, vol. 47, no. 6, pp. 1206–1208, 2002. View at Publisher · View at Google Scholar
  11. H Kobayashi, K Horikoshi, L Long, A Yamataka, G J Lane, and T Miyano, “Serum concentration of adhesion molecules in postoperative biliary atresia patients: relationship to disease activity and cirrhosis,” Journal of Pediatric Surgery, vol. 36, no. 8, pp. 1297–1301, 2001. View at Publisher · View at Google Scholar
  12. F Capra, E De Maria, C Lunardi et al., “Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: a prognostic marker for responses to interferon treatment,” Journal of Infectious Diseases, vol. 181, no. 2, pp. 425–431, 2000. View at Publisher · View at Google Scholar
  13. F Tacke, P Schöffski, C Trautwein et al., “Plasma P-selectin levels are elevated in patients with chronic liver disease,” Blood Coagulation and Fibrinolysis, vol. 14, no. 4, pp. 319–325, 2003. View at Publisher · View at Google Scholar
  14. M Cervello, L Virruso, G Lipani et al., “Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 126, no. 6, pp. 345–351, 2000. View at Publisher · View at Google Scholar
  15. T Eriksson, S Björkman, and P Höglund, “Clinical pharmacology of thalidomide,” European Journal of Clinical Pharmacology, vol. 57, no. 5, pp. 365–376, 2001. View at Publisher · View at Google Scholar
  16. S V Rajkumar, “Current status of thalidomide in the treatment of cancer,” Oncology (Huntington), vol. 15, no. 7, pp. 867–874, 877–879, 2001. View at Google Scholar
  17. B Settles, A Stevenson, K Wilson et al., “Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TN F-α agent thalidomide,” Cellular and Molecular Biology (Noisy-le-Grand), vol. 47, no. 7, pp. 1105–1114, 2001. View at Google Scholar
  18. C Meierhofer, S Dunzendorfer, and C J Wiedermann, “Theoretical basis for the activity of thalidomide,” BioDrugs, vol. 15, no. 10, pp. 681–703, 2001. View at Publisher · View at Google Scholar
  19. L García, I Hernández, A Sandoval et al., “Pirfenidone effectively reverses experimental liver fibrosis,” Journal of Hepatology, vol. 37, no. 6, pp. 797–805, 2002. View at Google Scholar
  20. M Pinzani and K Rombouts, “Liver fibrosis: from the bench to clinical targets,” Digestive and Liver Disease, vol. 36, no. 4, pp. 231–242, 2004. View at Publisher · View at Google Scholar
  21. J Garcia-Bañuelos, F Siller-Lopez, A Miranda, L K Aguilar, E Aguilar-Cordova, and J Armendariz-Borunda, “Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion,” Gene Therapy, vol. 9, no. 2, pp. 127–134, 2002. View at Google Scholar
  22. D C Rockey, “Antifibrotic therapy in chronic liver disease,” Clinical Gastroenterology and Hepatology, vol. 3, no. 2, pp. 95–107, 2005. View at Publisher · View at Google Scholar
  23. N Enomoto, Y Takei, M Hirose, T Kitamura, K Ikejima, and N Sato, “Protective effect of thalidomide on endotoxin-induced liver injury,” Alcoholism: Clinical and Experimental Research, vol. 27, no. 8 suppl, pp. 2S–6S, 2003. View at Publisher · View at Google Scholar
  24. A S Austin, Y R Mahida, D Clarke, S D Ryder, and J G Freeman, “A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis,” Alimentary Pharmacology and Therapeutics, vol. 19, no. 1, pp. 79–88, 2004. View at Publisher · View at Google Scholar
  25. Y Z Patt, M M Hassan, R D Lozano et al., “Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial,” Cancer, vol. 103, no. 4, pp. 749–755, 2005. View at Publisher · View at Google Scholar
  26. C Hsu, J C-H Cheng, and A-L Cheng, “Recent advances in non-surgical treatment for advanced hepatocellular carcinoma,” Journal of the Formosan Medical Association, vol. 103, no. 7, pp. 483–495, 2004. View at Google Scholar
  27. T-E Wang, C-R Kao, S-C Lin et al., “Salvage therapy for hepatocellular carcinoma with thalidomide,” World Journal of Gastroenterology, vol. 10, no. 5, pp. 649–653, 2004. View at Google Scholar
  28. A Thiele, R Bang, M Gütschow et al., “Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide,” European Journal of Pharmacology, vol. 453, no. 2-3, pp. 325–334, 2002. View at Publisher · View at Google Scholar
  29. J-P Raufman and L W Lamps, “Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C,” American Journal of Gastroenterology, vol. 96, no. 11, pp. 3209–3211, 2001. View at Publisher · View at Google Scholar
  30. P Muriel, E Fernández-Martínez, V Pérez-Álvarez et al., “Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat,” European Journal of Gastroenterology and Hepatology, vol. 15, no. 9, pp. 951–957, 2003. View at Publisher · View at Google Scholar
  31. T-S Yeh, Y-P Ho, S-F Huang, J-N Yeh, Y-Y Jan, and M-F Chen, “Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats,” Journal of Hepatology, vol. 41, no. 4, pp. 606–612, 2004. View at Publisher · View at Google Scholar
  32. P P Simeonova, R M Gallucci, T Hulderman et al., “The role of tumor necrosis factor-α in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride,” Toxicology and Applied Pharmacology, vol. 177, no. 2, pp. 112–120, 2001. View at Publisher · View at Google Scholar
  33. K Sudo, Y Yamada, H Moriwaki, K Saito, and M Seishima, “Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice,” Cytokine, vol. 29, no. 5, pp. 236–244, 2005. View at Publisher · View at Google Scholar
  34. R JR Singh, J C Mason, E A Lidington et al., “Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3,” Cardiovascular Research, vol. 67, no. 1, pp. 39–49, 2005. View at Publisher · View at Google Scholar
  35. K Maeda, K Yoshida, I Ichimiya, and M Suzuki, “Dexamethasone inhibits tumor necrosis factor-α-induced cytokine secretion from spiral ligament fibrocytes,” Hearing Resaerch, vol. 202, no. 1-2, pp. 154–160, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. C-H Woo, J-H Lim, and J-H Kim, “VCAM-1 upregulation via PKCδ-p38 kinase-linked cascade mediates the TNF-α-induced leukocyte adhesion and emigration in the lung airway epithelium,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 288, no. 2 32-2, pp. L307–L316, 2005. View at Publisher · View at Google Scholar
  37. N Kumagai, K Fukuda, Y Fujitsu, and T Nishida, “Expression of functional ICAM-1 on cultured human keratocytes induced by tumor necrosis factor-α,” Japanese Journal of Ophthalmology, vol. 47, no. 2, pp. 134–141, 2003. View at Publisher · View at Google Scholar
  38. M Sasaki, D Ostanin, J W Elrod et al., “TNF-α-induced endothelial cell adhesion molecule expression is cytochrome P-450 monooxygenase dependent,” American Journal of Physiology - Cell Physiology, vol. 284, no. 2 53-2, pp. C422–C428, 2003. View at Google Scholar
  39. M Schäefers, C Schmidt, C Vogel, K V Toyka, and C Sommer, “Tumor necrosis factor-α (TNF) regulates the expression of ICAM-1 predomonantly through TNF receptor 1 after chronic constriction injury of mouse sciatic nerve,” Acta Neuropathologica (Berlin), vol. 104, no. 2, pp. 197–205, 2002. View at Google Scholar
  40. N M Dagia, N Harii, A E Meli et al., “Phenyl methimazole inhibits TNF-α-induced VCAM-1 expression in an IFN regulatory factor-1-dependent manner and reduces monocytic cell adhesion to endothelial cells,” Journal of Immunology, vol. 173, no. 3, pp. 2041–2049, 2004. View at Google Scholar
  41. C H Hang, J-X Shi, J-S Li, W Wu, and X Y Hong, “Concomitant upregulation of nuclear factor-κB activity, proinflammatory cytokines and ICAM-1 in the injured brain after cortical contusion trauma in a rat model,” Neurology India, vol. 53, no. 3, pp. 312–317, 2005. View at Google Scholar
  42. E-W Son, S-J Mo, D-K Rhee, and S Pyo, “Vitamin C blocks TNF-α-induced NF-κB activation and ICAM-1 expression in human neuroblastoma cells,” Archives of Pharmacal Research, vol. 27, no. 10, pp. 1073–1079, 2004. View at Google Scholar
  43. L Lu, S S Chen, J Q Zhang, F J Ramires, and Y Sun, “Activation of nuclear factor-κB and its proinflammatory mediator cascade in the infarcted rat heart,” Biochemical and Biophysical Research Communications, vol. 321, no. 4, pp. 879–885, 2004. View at Publisher · View at Google Scholar
  44. Y-H Paik, R F Schwabe, R Bataller, M P Russo, C Jobin, and D A Brenner, “Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells,” Hepatology, vol. 37, no. 5, pp. 1043–1055, 2003. View at Publisher · View at Google Scholar
  45. A L Moreira, E P Sampaio, A Zmuidzinas, P Frindt, K A Smith, and G Kaplan, “Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation,” Journal of Experimental Medicine, vol. 177, no. 6, pp. 1675–1680, 1993. View at Publisher · View at Google Scholar
  46. E P Sampaio, M O Hernandez, D S Carvalho, and E N Sarno, “Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFα production in vitro,” Biomedicine and Pharmacotherapy, vol. 56, no. 1, pp. 13–19, 2002. View at Publisher · View at Google Scholar
  47. J A Keifer, D C Guttridge, B P Ashburner, and A S Jr Baldwin, “Inhibition of NF-κB activity by thalidomide through suppression of Iκ B kinase activity,” Journal of Biological Chemistry, vol. 276, no. 25, pp. 22382–22387, 2001. View at Publisher · View at Google Scholar